These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Systemic administration of recombinant interleukin-6 in mice induces proliferation of lymphoid cells in vivo. Puri RK; Leland P Lymphokine Cytokine Res; 1992 Jun; 11(3):133-9. PubMed ID: 1391232 [TBL] [Abstract][Full Text] [Related]
29. Generation and characterization of purified adherent lymphokine-activated killer cells in mice. Gunji Y; Vujanovic NL; Hiserodt JC; Herberman RB; Gorelik E J Immunol; 1989 Mar; 142(5):1748-54. PubMed ID: 2783950 [TBL] [Abstract][Full Text] [Related]
30. Lymphokine-activated effector cells: modulation of activity by cytokines. Mehta S; Flanagan P; Blackinton D; Wanebo H Lymphokine Cytokine Res; 1992 Apr; 11(2):73-7. PubMed ID: 1581419 [TBL] [Abstract][Full Text] [Related]
31. Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts. LeFor AT; Eisenthal A; Rosenberg SA J Immunol; 1988 Jun; 140(11):4062-9. PubMed ID: 3259603 [TBL] [Abstract][Full Text] [Related]
32. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells. Ettinghausen SE; Lipford EH; Mulé JJ; Rosenberg SA J Immunol; 1985 Nov; 135(5):3623-35. PubMed ID: 3900213 [TBL] [Abstract][Full Text] [Related]
33. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma. Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355 [TBL] [Abstract][Full Text] [Related]
34. In vivo activation of natural killer cells and priming of IL-2 responsive cytolytic cells by loxoribine (7-allyl-8-oxoguanosine). Pope BL; Chourmouzis E; Sigindere J; MacIntyre JP; Capetola RJ; Lau CY Cell Immunol; 1993 Apr; 147(2):302-12. PubMed ID: 8453674 [TBL] [Abstract][Full Text] [Related]
35. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells. Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622 [TBL] [Abstract][Full Text] [Related]
36. Precursor phenotype of lymphokine-activated killer cells in the mouse. Salup RR; Mathieson BJ; Wiltrout RH J Immunol; 1987 Jun; 138(11):3635-9. PubMed ID: 3108370 [TBL] [Abstract][Full Text] [Related]
37. In vivo treatment with interferon causes augmentation of IL-2 induced lymphokine-activated killer cells in the organs of mice. Puri RK; Leland P Clin Exp Immunol; 1991 Aug; 85(2):317-25. PubMed ID: 1713814 [TBL] [Abstract][Full Text] [Related]
38. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types. Papa MZ; Mulé JJ; Rosenberg SA Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517 [TBL] [Abstract][Full Text] [Related]
40. Generation of lymphokine-activated killer cells in strain 2 guinea pigs and their use in the therapy of L2C, an acute B-cell leukemia. Gregg EO; Gregg IC; Green I Cancer Res; 1987 Feb; 47(3):723-9. PubMed ID: 3492265 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]